February 2013 Life Science Industry Research Reports

Available at 30% discount till 31st January 2016 New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer.   Large global pharma are constantly on the hunt for drugs with label […]

Available at 30% discount till 31st January 2016 Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to […]